Direct and Indirect Costs of Influenza-Like Illness Treated with and Without Oseltamivir in 15 European Countries: A Descriptive Analysis Alongside the Randomised Controlled ALIC(4)E Trial
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Direct and Indirect Costs of Influenza-Like Illness Treated with and Without Oseltamivir in 15 European Countries : A Descriptive Analysis Alongside the Randomised Controlled ALIC(4)E Trial. / Li, Xiao; Bilcke, Joke; van der Velden, Alike W.; Bongard, Emily; Bruyndonckx, Robin; Sundvall, Par-Daniel; Harbin, Nicolay J.; Coenen, Samuel; Francis, Nick; Bruno, Pascale; Garcia-Sangenis, Ana; Glinz, Dominik; Kosiek, Katarzyna; Miko-Pauer, Reka; Radzeviciene Jurgute, Ruta; Seifert, Bohumil; Tsakountakis, Nikolaos; Aabenhus, Rune; Butler, Christopher C.; Beutels, Philippe.
In: Clinical Drug Investigation, Vol. 41, 2021, p. 685–699.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Direct and Indirect Costs of Influenza-Like Illness Treated with and Without Oseltamivir in 15 European Countries
T2 - A Descriptive Analysis Alongside the Randomised Controlled ALIC(4)E Trial
AU - Li, Xiao
AU - Bilcke, Joke
AU - van der Velden, Alike W.
AU - Bongard, Emily
AU - Bruyndonckx, Robin
AU - Sundvall, Par-Daniel
AU - Harbin, Nicolay J.
AU - Coenen, Samuel
AU - Francis, Nick
AU - Bruno, Pascale
AU - Garcia-Sangenis, Ana
AU - Glinz, Dominik
AU - Kosiek, Katarzyna
AU - Miko-Pauer, Reka
AU - Radzeviciene Jurgute, Ruta
AU - Seifert, Bohumil
AU - Tsakountakis, Nikolaos
AU - Aabenhus, Rune
AU - Butler, Christopher C.
AU - Beutels, Philippe
PY - 2021
Y1 - 2021
N2 - Background and Objective Influenza-like illness (ILI) leads to a substantial disease burden every winter in Europe; however, oseltamivir is not frequently prescribed to ILI patients in the primary-care setting. An open-label, multi-country, multi-season, randomised controlled trial investigated the effectiveness of oseltamivir for treating ILI in 15 European countries. We aimed to evaluate whether patients presenting with ILI in primary care and being managed with the addition of oseltamivir to usual care had lower average direct and indirect costs compared to patients with usual care alone. Methods Resource use data were extracted from participants' daily diaries. Itemised country-specific unit costs were collected through official tariffs, pharmacies or literature. Costs were converted to 2018 values. The null hypothesis was tested based on one-sided credible intervals (CrIs) obtained by bootstrapping. Base-case analysis estimated direct cost and productivity losses using itemised costed resource use and the human capital approach. Scenario analyses with self-reported spending rather than itemised costing were also performed. Results Patients receiving oseltamivir (N = 1306) reported fewer healthcare visits, medication uses, hospital attendances and paid-work hours lost than the other patients (N = 1298). Excluding the oseltamivir cost, the average direct costs were lower in patients treated with oseltamivir from all perspectives, but these differences were not statistically significant (perspective of patient: euro17 [0-95% Crl: 16-19] vs. euro24 [5-100% Crl: 18-29]; healthcare provider: euro37 [28-67] vs. euro44 [25-55]; healthcare payers: euro54 [45-85] vs. euro68 [45-81]; and society: euro423 [399-478] vs. euro451 [390-478]). Scenario and age-group analyses confirmed these findings, but with some between-country differences. Conclusion The average direct and indirect costs were consistently lower in patients treated with oseltamivir than in patients without from four perspectives (excluding the oseltamivir cost). However, these differences were not statistically significant.
AB - Background and Objective Influenza-like illness (ILI) leads to a substantial disease burden every winter in Europe; however, oseltamivir is not frequently prescribed to ILI patients in the primary-care setting. An open-label, multi-country, multi-season, randomised controlled trial investigated the effectiveness of oseltamivir for treating ILI in 15 European countries. We aimed to evaluate whether patients presenting with ILI in primary care and being managed with the addition of oseltamivir to usual care had lower average direct and indirect costs compared to patients with usual care alone. Methods Resource use data were extracted from participants' daily diaries. Itemised country-specific unit costs were collected through official tariffs, pharmacies or literature. Costs were converted to 2018 values. The null hypothesis was tested based on one-sided credible intervals (CrIs) obtained by bootstrapping. Base-case analysis estimated direct cost and productivity losses using itemised costed resource use and the human capital approach. Scenario analyses with self-reported spending rather than itemised costing were also performed. Results Patients receiving oseltamivir (N = 1306) reported fewer healthcare visits, medication uses, hospital attendances and paid-work hours lost than the other patients (N = 1298). Excluding the oseltamivir cost, the average direct costs were lower in patients treated with oseltamivir from all perspectives, but these differences were not statistically significant (perspective of patient: euro17 [0-95% Crl: 16-19] vs. euro24 [5-100% Crl: 18-29]; healthcare provider: euro37 [28-67] vs. euro44 [25-55]; healthcare payers: euro54 [45-85] vs. euro68 [45-81]; and society: euro423 [399-478] vs. euro451 [390-478]). Scenario and age-group analyses confirmed these findings, but with some between-country differences. Conclusion The average direct and indirect costs were consistently lower in patients treated with oseltamivir than in patients without from four perspectives (excluding the oseltamivir cost). However, these differences were not statistically significant.
KW - HEALTHY-ADULTS
KW - CARE
U2 - 10.1007/s40261-021-01057-y
DO - 10.1007/s40261-021-01057-y
M3 - Journal article
C2 - 34292510
VL - 41
SP - 685
EP - 699
JO - Clinical Drug Investigation
JF - Clinical Drug Investigation
SN - 1173-2563
ER -
ID: 275266607